ISNTD d³ 2021 addresses the current gaps and collaboration opportunities across tropical diseases and diseases of poverty to accelerate drug discovery & development, vaccine R&D and uptake, and diagnostics and surveillance opportunities.
This year, against the backdrop of the recently launched WHO NTD Roadmap and the shock of the COVID-19 pandemic, ISNTD d³ focuses on the shifts, gaps, and future needs of drug discovery, treatments, and diagnostics in context of global health as well as broader challenges.
Panel discussions
Rethinking financial incentives for drugs and diagnostics for Neglected Tropical Diseases
Date: Wednesday, 24 February 2021
Time: 9.00-10.00 UTC
Chair: Andrew Jack, Financial Times
Speakers:
- Dr Hayato Urabe, Senior Director, Investment Strategy, Portfolio Development & Innovations, GHIT Fund
- Olawale Ajose, Head of Access, Neglected Tropical Diseases, DNDi
- Dr Beatrice Greco, Head of R&D and Access, Global Health Institute, Merck
- Margo Warren, Government Engagement & Policy Manager, Access to Medicine Foundation
Putting access at the centre of future drug development
Date: Wednesday, 24 February 2021
Time: 10.15-11.45 UTC
Speakers:
- Margo Warren, Government Engagement & Policy Manager, Access to Medicine Foundation
- Dr Isaac Chikwanha, Senior Director: Investment Strategy, Access & Delivery, GHIT Fund
- Olawale Ajose, Head of Access, Neglected Tropical Diseases, DNDi
- The Leprosy Mission England & Wales patient voices
Drug repurposing for COVID19 & neglected tropical diseases
Date: Wednesday, 24 February 2021
Time: 13.15-14.45 UTC
Speakers:
- Dr Nathalie Strub-Wourgaft, Director of Neglected Tropical Diseases, DNDi
- Heather Stone, Health Science Policy Analyst, US Food & Drug Administration
Focus: leishmaniasis
Date: Wednesday, 24 February 2021
Time: 15.00-16.30 UTC
| Current and future treatments for visceral leishmaniasis Prof Maria Paola Costi, Drug Discovery and Biotechnology Lab, University of Modena and Reggio Emilia, UNIMORE Dr Fabiana Alves, Head of Visceral Leishmaniasis Clinical Programme, DNDi |
| The development of new treatments for cutaneous leishmaniasis, opportunities, and gaps Dr Byron Arana, Head of Cutaneous Leishmaniasis, DNDi |
| Topical treatments for cutaneous leishmaniasis Prof Dolores Carrer, Biophysics and Nanotechnology Lab, INIMEC-CONICET-UNC, Argentina |
| Biophysical characterization and integrated MD simulation studies of trypanothione reductase in leishmania major Anurag Kumar, Computational & Systems Biology Lab, National Centre For Cell Science, Pune, Maharashtra, India |
